About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
March 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Twitter List
Legislative Tracking Tools
Category Archives: Approvable Letters
Impact of Approvable Letters 2007 – Part 1
I do not currently have a way of counting and comparing the number of approvable letters issued over the past few years, but my gut tells me that 2007 was a banner year. I am currently compiling the 2007 list … Continue reading
Posted in Approvable Letters
Comments Off on Impact of Approvable Letters 2007 – Part 1
Approvable Letter Mania
I am beginning to believe that there have been a flood of approvable letters, though I haven’t gone back over the years to count the rate – but my gut tells me that the rate has increased. It is a … Continue reading
Posted in Approvable Letters
2 Comments
Neurochem Gets Approvable Letter
The FDA has issued another approvable letter – this time to Neurochem for eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis. This was not good news on two fronts – first, it was the product’s second approvable letter … Continue reading
Posted in Approvable Letters
Comments Off on Neurochem Gets Approvable Letter
What’s at Stake with Formal Dispute Resolution
Recently, two pharmaceutical companies announced that they would be seeking Formal Dispute Resolution (FDR) because of FDA decisions regarding their products. Genta announced in April that the company would be filing one over a non-approvable letter for their investigative product … Continue reading
Posted in Approvable Letters
Comments Off on What’s at Stake with Formal Dispute Resolution
Two More Approvable Letters Issued
Wow – the approvable letters are flying off the shelves. If you are not familiar with approvable letters, see my posting "What Does Approvable Mean?" Or you may wish to listen to my podcast on the subject of approvable letters. … Continue reading
Posted in Approvable Letters
Comments Off on Two More Approvable Letters Issued